Use of midazolam as a human cytochrome P450 3A probe

I. In vitro-in vivo correlations in liver transplant patients

K. E. Thummel, D. D. Shen, T. D. Podoll, K. L. Kunze, W. F. Trager, P. S. Hartwell, V. A. Raisys, C. L. Marsh, John McVicar, D. M. Barr, J. D. Perkins, R. L. Carithers

Research output: Contribution to journalArticle

304 Citations (Scopus)

Abstract

The clearance of midazolam (MDZ) in humans is principally due to metabolic biotransformation catalyzed by CYP3A isoforms. A study was conducted in patients who had undergone liver transplants that provides evidence that MDZ can be used as an in vivo probe of interindividual hepatic CYP3A variability. The clearance of MDZ and cyclosporine after i.v. administration were determined in 10 patients approximately 10 days after transplant surgery. Liver biopsy specimens were obtained within 24 hr of the pharmacokinetic study and CYP3A content and MDZ 1'-hydroxylation activity were measured in 13,000 x g tissue supernatants (S-13). The in vitro rate of 1'-hydroxy-MDZ formation was found to correlate significantly with the total CYP3A content in hepatic S-13 fractions (r = .84, P < .01). The total MDZ clearance measured in vivo was highly correlated with the hepatic CYP3A content measured in vitro (r = .93, P < .001) and with in vivo cyclosporine clearance (r = .81, P < .001). For five of the patients, the intrinsic clearance of midazolam to 1'-hydroxy-MDZ (V(max)/K(m)) in vitro measured in S-13 preparations was scaled for total liver mass and applied to the well stirred model of hepatic clearance to yield a prediction of MDZ clearance in vivo. The mean MDZ clearance predicted from in vitro 1'-hydroxylation data was identical to the mean clearance observed in vivo (0.60 ± 0.24 versus 0.59 ± 0.25 liter/min). Together, the results suggest that variability in hepatic CYP3A expression in liver transplant recipients, and possibly in other populations, can be determined by the measurement of MDZ metabolic clearance.

Original languageEnglish (US)
Pages (from-to)549-556
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume271
Issue number1
StatePublished - 1994
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP3A
Midazolam
Transplants
Liver
5-chloro-3-tert-butyl-2'-chloro-4'-nitrosalicylanilide
Hydroxylation
Cyclosporine
In Vitro Techniques
Biotransformation
Protein Isoforms
Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Thummel, K. E., Shen, D. D., Podoll, T. D., Kunze, K. L., Trager, W. F., Hartwell, P. S., ... Carithers, R. L. (1994). Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. Journal of Pharmacology and Experimental Therapeutics, 271(1), 549-556.

Use of midazolam as a human cytochrome P450 3A probe : I. In vitro-in vivo correlations in liver transplant patients. / Thummel, K. E.; Shen, D. D.; Podoll, T. D.; Kunze, K. L.; Trager, W. F.; Hartwell, P. S.; Raisys, V. A.; Marsh, C. L.; McVicar, John; Barr, D. M.; Perkins, J. D.; Carithers, R. L.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 271, No. 1, 1994, p. 549-556.

Research output: Contribution to journalArticle

Thummel, KE, Shen, DD, Podoll, TD, Kunze, KL, Trager, WF, Hartwell, PS, Raisys, VA, Marsh, CL, McVicar, J, Barr, DM, Perkins, JD & Carithers, RL 1994, 'Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients', Journal of Pharmacology and Experimental Therapeutics, vol. 271, no. 1, pp. 549-556.
Thummel, K. E. ; Shen, D. D. ; Podoll, T. D. ; Kunze, K. L. ; Trager, W. F. ; Hartwell, P. S. ; Raisys, V. A. ; Marsh, C. L. ; McVicar, John ; Barr, D. M. ; Perkins, J. D. ; Carithers, R. L. / Use of midazolam as a human cytochrome P450 3A probe : I. In vitro-in vivo correlations in liver transplant patients. In: Journal of Pharmacology and Experimental Therapeutics. 1994 ; Vol. 271, No. 1. pp. 549-556.
@article{ab5e4e771ac94b079e186d78fb9ec0fc,
title = "Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients",
abstract = "The clearance of midazolam (MDZ) in humans is principally due to metabolic biotransformation catalyzed by CYP3A isoforms. A study was conducted in patients who had undergone liver transplants that provides evidence that MDZ can be used as an in vivo probe of interindividual hepatic CYP3A variability. The clearance of MDZ and cyclosporine after i.v. administration were determined in 10 patients approximately 10 days after transplant surgery. Liver biopsy specimens were obtained within 24 hr of the pharmacokinetic study and CYP3A content and MDZ 1'-hydroxylation activity were measured in 13,000 x g tissue supernatants (S-13). The in vitro rate of 1'-hydroxy-MDZ formation was found to correlate significantly with the total CYP3A content in hepatic S-13 fractions (r = .84, P < .01). The total MDZ clearance measured in vivo was highly correlated with the hepatic CYP3A content measured in vitro (r = .93, P < .001) and with in vivo cyclosporine clearance (r = .81, P < .001). For five of the patients, the intrinsic clearance of midazolam to 1'-hydroxy-MDZ (V(max)/K(m)) in vitro measured in S-13 preparations was scaled for total liver mass and applied to the well stirred model of hepatic clearance to yield a prediction of MDZ clearance in vivo. The mean MDZ clearance predicted from in vitro 1'-hydroxylation data was identical to the mean clearance observed in vivo (0.60 ± 0.24 versus 0.59 ± 0.25 liter/min). Together, the results suggest that variability in hepatic CYP3A expression in liver transplant recipients, and possibly in other populations, can be determined by the measurement of MDZ metabolic clearance.",
author = "Thummel, {K. E.} and Shen, {D. D.} and Podoll, {T. D.} and Kunze, {K. L.} and Trager, {W. F.} and Hartwell, {P. S.} and Raisys, {V. A.} and Marsh, {C. L.} and John McVicar and Barr, {D. M.} and Perkins, {J. D.} and Carithers, {R. L.}",
year = "1994",
language = "English (US)",
volume = "271",
pages = "549--556",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Use of midazolam as a human cytochrome P450 3A probe

T2 - I. In vitro-in vivo correlations in liver transplant patients

AU - Thummel, K. E.

AU - Shen, D. D.

AU - Podoll, T. D.

AU - Kunze, K. L.

AU - Trager, W. F.

AU - Hartwell, P. S.

AU - Raisys, V. A.

AU - Marsh, C. L.

AU - McVicar, John

AU - Barr, D. M.

AU - Perkins, J. D.

AU - Carithers, R. L.

PY - 1994

Y1 - 1994

N2 - The clearance of midazolam (MDZ) in humans is principally due to metabolic biotransformation catalyzed by CYP3A isoforms. A study was conducted in patients who had undergone liver transplants that provides evidence that MDZ can be used as an in vivo probe of interindividual hepatic CYP3A variability. The clearance of MDZ and cyclosporine after i.v. administration were determined in 10 patients approximately 10 days after transplant surgery. Liver biopsy specimens were obtained within 24 hr of the pharmacokinetic study and CYP3A content and MDZ 1'-hydroxylation activity were measured in 13,000 x g tissue supernatants (S-13). The in vitro rate of 1'-hydroxy-MDZ formation was found to correlate significantly with the total CYP3A content in hepatic S-13 fractions (r = .84, P < .01). The total MDZ clearance measured in vivo was highly correlated with the hepatic CYP3A content measured in vitro (r = .93, P < .001) and with in vivo cyclosporine clearance (r = .81, P < .001). For five of the patients, the intrinsic clearance of midazolam to 1'-hydroxy-MDZ (V(max)/K(m)) in vitro measured in S-13 preparations was scaled for total liver mass and applied to the well stirred model of hepatic clearance to yield a prediction of MDZ clearance in vivo. The mean MDZ clearance predicted from in vitro 1'-hydroxylation data was identical to the mean clearance observed in vivo (0.60 ± 0.24 versus 0.59 ± 0.25 liter/min). Together, the results suggest that variability in hepatic CYP3A expression in liver transplant recipients, and possibly in other populations, can be determined by the measurement of MDZ metabolic clearance.

AB - The clearance of midazolam (MDZ) in humans is principally due to metabolic biotransformation catalyzed by CYP3A isoforms. A study was conducted in patients who had undergone liver transplants that provides evidence that MDZ can be used as an in vivo probe of interindividual hepatic CYP3A variability. The clearance of MDZ and cyclosporine after i.v. administration were determined in 10 patients approximately 10 days after transplant surgery. Liver biopsy specimens were obtained within 24 hr of the pharmacokinetic study and CYP3A content and MDZ 1'-hydroxylation activity were measured in 13,000 x g tissue supernatants (S-13). The in vitro rate of 1'-hydroxy-MDZ formation was found to correlate significantly with the total CYP3A content in hepatic S-13 fractions (r = .84, P < .01). The total MDZ clearance measured in vivo was highly correlated with the hepatic CYP3A content measured in vitro (r = .93, P < .001) and with in vivo cyclosporine clearance (r = .81, P < .001). For five of the patients, the intrinsic clearance of midazolam to 1'-hydroxy-MDZ (V(max)/K(m)) in vitro measured in S-13 preparations was scaled for total liver mass and applied to the well stirred model of hepatic clearance to yield a prediction of MDZ clearance in vivo. The mean MDZ clearance predicted from in vitro 1'-hydroxylation data was identical to the mean clearance observed in vivo (0.60 ± 0.24 versus 0.59 ± 0.25 liter/min). Together, the results suggest that variability in hepatic CYP3A expression in liver transplant recipients, and possibly in other populations, can be determined by the measurement of MDZ metabolic clearance.

UR - http://www.scopus.com/inward/record.url?scp=0028114619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028114619&partnerID=8YFLogxK

M3 - Article

VL - 271

SP - 549

EP - 556

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -